Status:
COMPLETED
Helicobacter Pylori Eradication Therapy for Immune Thrombocytopenia (ITP) Patients in Iraq
Lead Sponsor:
Al-Mustansiriyah University
Conditions:
Immune Thrombocytopenic Purpura
HELICOBACTER PYLORI INFECTIONS
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is being conducted to evaluate the effect of treating Helicobacter pylori infection on platelet counts in patients with immune thrombocytopenia (ITP). ITP is a condition in which the body's...
Detailed Description
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelet counts and increased bleeding risk. Several studies have suggested a link between Helicobacter pylori inf...
Eligibility Criteria
Inclusion
- Adults (≥18 years) with a confirmed diagnosis of ITP Platelet count \<100,000/µL. H. pylori-positive or H. pylori-negative based on stool antigen test
Exclusion
- • Patients with other causes of thrombocytopenia (e.g., leukemia, aplastic anemia).
- Severe comorbidities (e.g., uncontrolled diabetes, severe cardiac disease).
- Recent use (within 4 weeks) of antibiotics, proton pump inhibitors, or bismuth compounds.
- Concurrent use of medications that interfere with H. pylori therapy or platelet levels.
- Pregnant or lactating women.
- Known allergy or intolerance to eradication therapy agents (clarithromycin, amoxicillin, metronidazole).
- High risk of poor compliance (e.g., psychiatric illness).
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07150286
Start Date
September 1 2024
End Date
April 1 2025
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Mustansiriyah University - college of pharmacy - clinical pharmacy department
Baghdad, Baghdad Governorate, Iraq, 10001